Skip to main content
Premium Trial:

Request an Annual Quote

Trovagene Closes CLIA Lab Acquisition

NEW YORK (GenomeWeb News) – Trovagene today said it has completed its acquisition of the CLIA laboratory of MultiGen Diagnostics.

Trovagene announced the deal with the privately held molecular diagnostic subsidiary of Bio-ID Diagnostics in early January. The lab is certified by the State of California in compliance with CLIA and is accredited by the College of American Pathologists.

As part of the deal, Trovagene is issuing 750,000 shares of its common stock with an additional earn-out of up to $3.7 million in cash and common stock, subject to the lab achieving specific sales and earnings targets.

MultiGen continues to operate as a molecular diagnostics company focused on DNA sequencing-based identification services.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.